MTOR and lymphatic malformation: For instance, the mTOR inhibitor Sirolimus (Rapamycin), which inhibits the PI3K-Akt pathway downstream of PI3K, has been trialed in patients with slow-flow malformations, showing the greatest efficacy in lymphatic malformations with evidence for reduced lesion volume and improved management of comorbidities, such as pain, bleeding, and quality of life.11